Zorloni Gabriele, Bosmans Geert, Brall Thomas, Caresana Marco, De Saint-Hubert Marijke, Domingo Carles, Ferrante Christian, Ferrulli Francesca, Kopec Renata, Leidner Johannes, Mares Vladimir, Nabha Racell, Olko Pawel, Caballero-Pacheco Miguel Ángel, Ruehm Werner, Silari Marco, Stolarczyk Liliana, Swakon Jan, Tisi Marco, Trinkl Sebastian, Van Hoey Olivier, Vilches-Freixas Gloria
CERN, Esplanade des Particules 1, Geneve, 1211, SWITZERLAND.
Maastricht University Medical Centre+ Oncology Centre, P. Debyelaan 25, Maastricht, Limburg, 6229, NETHERLANDS.
Phys Med Biol. 2022 Mar 8. doi: 10.1088/1361-6560/ac5b9c.
Objective Proton therapy is gaining popularity because of the improved dose delivery over conventional radiation therapy. The secondary dose to healthy tissues is dominated by secondary neutrons. Commercial rem-counters are valuable instruments for the on-line assessment of neutron ambient dose equivalent (H*(10)). In general, however, a priori knowledge of the type of facility and of the radiation field is required for the proper choice of any survey meter. The novel Mevion S250i Hyperscan synchrocyclotron mounts the accelerator directly on the gantry. It provides a scanned 227 MeV proton beam, delivered in pulses with a pulse width of 10 µs at 750 Hz frequency, which is afterwards degraded in energy by a range shifter modulator system. This environment is particularly challenging for commercial rem-counters; therefore, we tested the reliability of some of the most widespread rem-counters to understand their limits in the Mevion S250i stray neutron field. Approach This work, promoted by the European Radiation Dosimetry Group (EURADOS), describes a rem-counter intercomparison at the Maastro Proton Therapy centre in the Netherlands, which houses the novel Mevion S250i Hyperscan system. Several rem-counters were employed in the intercomparison (LUPIN, LINUS, WENDI-II, LB6411, NM2B-458, NM2B-495Pb), which included simulation of a patient treatment protocol employing a water tank phantom. The outcomes of the experiment were compared with models and data from the literature. Main results We found that only the LUPIN allowed for a correct assessment of H*(10) within a 20% uncertainty. All other rem-counters underestimated the reference H*(10) by factors from 2 to more than 10, depending on the detector model and on the neutron dose per pulse. In pulsed fields, the neutron dose per pulse is a fundamental parameter, while the average neutron dose rate is a secondary quantity. An average 150-200 µSv/GyRBE neutron H*(10) at various positions around the phantom and at distances between 186 cm and 300 cm from it was measured per unit therapeutic dose delivered to the target. Significance Our results are partially in line with results obtained at similar Mevion facilities employing passive energy modulation. Comparisons with facilities employing active energy modulation confirmed that the neutron H*(10) can increase up to more than a factor of 10 when passive energy modulation is employed. The challenging environment of the Mevion stray neutron field requires the use of specific rem-counters sensitive to high-energy neutrons (up to a few hundred MeV) and specifically designed to withstand pulsed neutron fields.
目的 由于质子治疗在剂量传递方面优于传统放射治疗,其应用越来越广泛。健康组织的次级剂量主要由次级中子主导。商用剂量仪是在线评估中子周围剂量当量(H*(10))的重要工具。然而,一般来说,要正确选择任何测量仪,需要事先了解设施类型和辐射场情况。新型Mevion S250i超扫描同步回旋加速器将加速器直接安装在机架上。它提供扫描式227 MeV质子束,以750 Hz频率、10 μs的脉冲宽度脉冲式发射,之后通过射程移位调制器系统降低能量。这种环境对商用剂量仪来说极具挑战性;因此,我们测试了一些最常用剂量仪的可靠性,以了解它们在Mevion S250i杂散中子场中的局限性。方法 这项由欧洲辐射剂量学小组(EURADOS)推动的工作,描述了在荷兰马斯特里赫特质子治疗中心进行的剂量仪比对,该中心配备了新型Mevion S250i超扫描系统。比对中使用了几种剂量仪(LUPIN、LINUS、WENDI-II、LB6411、NM2B - 458、NM2B - 495Pb),其中包括使用水箱体模模拟患者治疗方案。将实验结果与文献中的模型和数据进行了比较。主要结果 我们发现,只有LUPIN能够在20%的不确定度范围内正确评估H*(10)。所有其他剂量仪对参考H*(10)的低估因子在2到10以上,这取决于探测器型号和每脉冲的中子剂量。在脉冲场中,每脉冲的中子剂量是一个基本参数,而平均中子剂量率是一个次要量。每向靶区输送单位治疗剂量,在体模周围不同位置以及距离体模186 cm至300 cm处,测得平均150 - 200 μSv/GyRBE的中子H*(10)。意义 我们的结果部分与在采用被动能量调制的类似Mevion设施中获得的结果一致。与采用主动能量调制的设施进行比较证实,采用被动能量调制时,中子H*(10)可增加至10倍以上。Mevion杂散中子场的挑战性环境要求使用对高能中子(高达几百MeV)敏感且专门设计用于承受脉冲中子场的特定剂量仪。